Spyre Therapeutics (SYRE) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $56.9 million.
- Spyre Therapeutics' Operating Expenses rose 270.08% to $56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.6 million, marking a year-over-year increase of 1056.58%. This contributed to the annual value of $208.6 million for FY2024, which is 1423.71% down from last year.
- Latest data reveals that Spyre Therapeutics reported Operating Expenses of $56.9 million as of Q3 2025, which was up 270.08% from $41.9 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Operating Expenses ranged from a high of $159.9 million in Q2 2023 and a low of $18.2 million during Q1 2021
- Its 5-year average for Operating Expenses is $40.8 million, with a median of $25.8 million in 2022.
- In the last 5 years, Spyre Therapeutics' Operating Expenses skyrocketed by 59391.7% in 2023 and then tumbled by 7239.67% in 2024.
- Over the past 5 years, Spyre Therapeutics' Operating Expenses (Quarter) stood at $24.1 million in 2021, then decreased by 19.75% to $19.3 million in 2022, then surged by 137.53% to $45.9 million in 2023, then skyrocketed by 33.41% to $61.3 million in 2024, then dropped by 7.13% to $56.9 million in 2025.
- Its Operating Expenses was $56.9 million in Q3 2025, compared to $41.9 million in Q2 2025 and $53.6 million in Q1 2025.